Cancer Policy In the name of “radical transparency,” FDA touts publication of 200 complete response letters July 11, 2025Vol.51 No.27By Jacquelyn Cobb
Drugs & Targets FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins July 03, 2025Vol.51 No.26
Drugs & Targets FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM July 03, 2025Vol.51 No.26
Drugs & Targets REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated July 03, 2025Vol.51 No.26
Cancer Policy Jacqueline Corrigan-Curay to retire as acting head of CDER at FDA June 27, 2025Vol.51 No.25By Claire Marie Porter
Drugs & Targets FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated NSCLC June 27, 2025Vol.51 No.25
Drugs & Targets FDA grants Breakthrough Therapy designation for daraxonrasib in pancreatic cancer June 27, 2025Vol.51 No.25
Trials & Tribulations Optimizing dosing of expensive and toxic oncology drugs: Making America healthier June 20, 2025Vol.51 No.24By Mark J. Ratain, David A. Hyman, Jill E. Feldman, Beth R. Jacobson and Allen S. Lichter
Cancer Policy FDA to issue “national priority vouchers” to companies supporting U.S. interests June 20, 2025Vol.51 No.24By Claire Marie Porter
Cancer Policy Vinay Prasad named chief medical and scientific officer at FDA June 20, 2025Vol.51 No.24By Claire Marie Porter
